es

September 19, 2002

The Honorable Tommy G. Thompson

Secretary, U.S. Department of Health and Human Services

Hubert H. Humphrey Building

200 Independence Avenue, S.W.

Washington, DC 20201

Dear Secretary Thompson:

This letter is to express our deep concern about reports that the Administration is engaging in a wholesale replacement of the experts on key scientific advisory committees.


es

FOR IMMEDIATE RELEASE:

Tuesday, September 24, 2002

CONTACT: Ken Johnson or Vikki Riley

202.225.5735

Full Committee to Markup Medical Errors,

Medical Device User Fee, Other Health Bills


/index.php?option=com_iwpfile&file=/dir_01/he2002_2464.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2462.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2461.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2460.pdf

In a statement, OSHA Administrator John Henshaw praises the American Furniture Manufacturers Association and the North Carolina Department of Labor for their alliance designed to develop voluntary ergonomic guidelines. The alliance is the first of its kind, bringing federal and state government together with industry to develop voluntary ergonomics guidelines for a specific industry.


HHS Secretary Tommy Thompson calls on drug companies to make pharmaceuticals more affordable in a recent speech at the 15th annual Bear, Stearns Healthcare Conference.


Normal" style=" text-align: center;">Statement on Safety Issues Related to Acetaminophen

Before the Nonprescription Drugs Advisory Committee

September 19, 2002

In 1977, the Food and Drug Administration's (FDA's) Advisory Review Panel recommended the following warnings for acetaminophen-containing products: "Do not exceed recommended dosage because severe liver damage may occur" and "Do not exceed recommended dosage or take for more than 10 days, because severe liver damage may occur." The FDA chose to ignore this wise advice.


/index.php?option=com_iwpfile&file=/dir_01/he2002_2456.pdf

Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.